Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC

NCT05143099 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
35
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Shanghai Zhongshan Hospital